Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus albumin bound - Abraxis Bioscience

Drug Profile

Sirolimus albumin bound - Abraxis Bioscience

Alternative Names: ABI-009; albumin-bound rapamycin; FYARRO; Nab-rapamycin; Nab-sirolimus; TARZIFYX

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience
  • Developer Aadi Bioscience; Children's Oncology Group; Mirati Therapeutics; National Cancer Institute (USA); Ochsner Clinic Foundation; Seattle Children's Hospital; University of Washington
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Perivascular epithelioid cell tumours
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perivascular epithelioid cell tumours
  • Phase II Endometrial cancer; Glioblastoma; Glioma; Leigh disease; Neuroendocrine tumours; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer; Sarcoma; Soft tissue sarcoma
  • Phase I Epilepsy; Non-small cell lung cancer; Pulmonary arterial hypertension

Most Recent Events

  • 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
  • 14 Dec 2023 Interim efficacy and adverse events data from the phase II trial in Solid tumours released by Aadi Bioscience
  • 31 Oct 2023 Phase-II clinical trials in Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT05997056)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top